Trial · NCT06805864
Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma
NCT06805864, Phase 2, Not yet recruiting, Gunma University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma. Trials, record NCT06805864. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06805864
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma
- NCT number
- NCT06805864
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 45 participants, estimated
- Lead sponsor
- Gunma University
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
- Interventions
- Pembrolizumab (KEYTRUDA®)
- First posted
- 2025-02-03
- Last updated
- 2025-02-03
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | At 2 years after the start of trial treatment | It is based on the investigator's RECIST 1.1 assessment, or in the absence of imaging evidence of disease progression based on RECIST 1.1, histologically confirmed PD, after concurrent chemo-CIRT with pembrolizumab. |
| Secondary | Overall survival (OS) | At 2 years after the start of trial treatment | To evaluate the 2-year overall survival after concurrent chemo-CIRT with pembrolizumab. |
| Secondary | Complete response (CR) rate | At 6 months after the start of trial treatment | To evaluate the complete response (CR) rate, defined as the maximum response of the primary tumor based on RECIST 1.1 assessment at 6 months after initiation of CIRT. |
| Secondary | Local control (LC) | At 2 years after the start of trial treatment | To evaluate the 2-year local control (LC) after concurrent chemo-CIRT with pembrolizumab. |
| Secondary | Acute and late toxicities | Acute (≤ 90 days) and late toxicities (> 90 days) over 2 years after the start of trial treatment. | To evaluate the acute and late toxicities of concurrent chemo-CIRT with pembrolizumab. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06805864
GET https://conductscience.org/api/trials/v1/NCT06805864/registered